PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib
and erlotinib was evaluated as the second-line therapy for advanced non-small cell lung
cancer (NSCLC). PATIENTS AND METHODS: Patients with locally advanced, metastatic
stage IIIB/IV NSCLC who failed first-line chemotherapy and had either EGFR mutation or at
least two out of three clinical factors associated with higher incidence of EGFR mutations …

7551 Background: Gefitinib and erlotinib are potent inhibitors of the epidermal growth factor
receptor tyrosine kinase (EGFR TK), with single agent antitumor activity. In this randomized,
single-center, phase II trial, the efficacy and safety of gefitinib was compared with that of
erlotinib as the second-line therapy for advanced non-small cell lung cancer patients.
Methods: Patients with locally or metastatic stage IIIB or IV non-small cell lung cancer
(NSCLC), after failure of first line chemotherapy, were to assigned to gefitinib 250 mg or …